Reata Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RETA Reata Pharmaceuticals Inc
PVL Permianville Royalty Trust
FUPBY Fuchs Petrolub SE
JACK Jack in the Box Inc
NH NantHealth Inc
PWSC PowerSchool Holdings Inc
AEHL Antelope Enterprise Holdings Ltd
POR Portland General Electric Co
CUBI Customers Bancorp Inc

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. It is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Day's Change
-0.03 (-0.12%)
B/A Size
Day's High
Day's Low

Today's volume of 38,992 shares is on pace to be much lighter than RETA's 10-day average volume of 604,440 shares.

Annual Earnings Met Consensus (Year ending 12/2021)Next Earnings Announcement
Announced February 28, 2022
-$8.19Annual Estimate range
of 6 analysts
-$8.24 to -$7.872022 Earnings
will announce
(Unconfirmed) November 7, 2022

Annual Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

RETA's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.